Mirtazapine
- Generic Name
- Mirtazapine
- Brand Names
- Remeron
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3
- CAS Number
- 85650-52-8
- Unique Ingredient Identifier
- A051Q2099Q
- Background
Mirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder. The effects of this drug may be observed as early as 1 week after beginning therapy.
In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.
- Indication
This drug is indicated for the treatment of major depressive disorder and its associated symptoms.
Mirtazapine has been used off-label for a variety of conditions including panic disorder, generalized anxiety disorder, dysthymia, tension headaches, hot flushes, post-traumatic stress disorder (PTSD), sleep disorders, substance abuse disorders, and sexual disorders, among others.
- Associated Conditions
- Cancer Pain, Depression, Fibromyalgia, Generalized Anxiety Disorder, Hot Flashes, Insomnia, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Persistent Depressive Disorder (Dysthymia), Post Operative Nausea and Vomiting (PONV), Poststroke depression, Sleep disorders and disturbances, Substance Abuse Disorders, Tension Headache
Mirtazapine for Chronic Insomnia in Older Adults
- Conditions
- Chronic Insomnia
- Interventions
- Drug: Placebo oral tablet once daily at bedtime
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
- Target Recruit Count
- 60
- Registration Number
- NCT05247697
- Locations
- 🇨🇦
Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients With Advanced Stage Cancer
- Conditions
- Anorexia Nervosa with Significantly Low Body Weight
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Englewood Hospital and Medical Center
- Target Recruit Count
- 170
- Registration Number
- NCT05170919
- Locations
- 🇺🇸
Englewood Health, Englewood, New Jersey, United States
Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 210
- Registration Number
- NCT05108688
- Locations
- 🇪🇬
Ain-Shams University Hospitals, Cairo, Egypt
Emergence Agitation After Nasal Surgery: a Randomized Controlled Comparison Between Melatonin and Mirtazapine
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 165
- Registration Number
- NCT04908605
- Locations
- 🇪🇬
Ain-Shams University Hospitals, Cairo, Egypt
Role of Mirtazapine in Ameliorating Sleep Disordered Breathing
- Conditions
- Spinal Cord InjuriesSleep Disordered Breathing
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Wayne State University
- Target Recruit Count
- 18
- Registration Number
- NCT04799782
Mirtazapine in Cancer-related Poly-symptomatology
- Conditions
- CancerNeoplasm MetastasisNeoplasms
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 1
- Registration Number
- NCT04763135
- Locations
- 🇫🇷
Hôpitaux universitaires de Strasbourg, Strasbourg, France
🇫🇷Centre Hospitalier Lyon Sud, Pierre-Bénite, France
🇫🇷Centre Hospitalier Universitaire de Clermont-Ferrand, Cébazat, France
Effect of Mirtazapine Versus Placebo in Patients With Non-small Cell Lung Cancer and Anorexia
- Conditions
- AnorexiaNon-small Cell Lung Cancer
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Instituto Nacional de Cancerologia de Mexico
- Target Recruit Count
- 86
- Registration Number
- NCT04748523
- Locations
- 🇲🇽
Instituto Nacional de Cancerologia, Mexico City, Mexico
Improving Sleep After TKA Using Mirtazapine and Quetiapine
- Conditions
- Osteo Arthritis KneeInsomnia
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- St. Anna Ziekenhuis, Geldrop, Netherlands
- Target Recruit Count
- 165
- Registration Number
- NCT04728581
- Locations
- 🇳🇱
St. Anna hospital, Geldrop, Netherlands
🇳🇱Knowledge Center for Orthopedic Surgery, St. Anna hospital, Geldrop, Netherlands
Mirtazapine and Methamphetamine Drug-drug Interaction Study
- Conditions
- Methamphetamine Use DisorderDrug InteractionCardiovascular Abnormalities
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- San Francisco Department of Public Health
- Target Recruit Count
- 24
- Registration Number
- NCT04614584
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸San Francisco Department of Public Health, San Francisco, California, United States
🇺🇸Substance Use Research Unit, San Francisco, California, United States
Mirtazapine Versus Dexamethasone in Preventing Postoperative Nausea and Vomiting
- Conditions
- Post Operative Nausea and Vomiting
- Interventions
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 90
- Registration Number
- NCT04547842
- Locations
- 🇪🇬
Ain Shams University, Cairo, Abassia, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.